Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news

Show

From To
Starting HIV treatment at diagnosis slashes drop out, drug failure rates, China study finds

Patients diagnosed with HIV who started antiretroviral treatment within 30 days had significantly lower rates of dropping out of treatment, and higher rates successful treatment, than those who started later, particularly those who started more than three months after their diagnosis, a study in China has found.

Published
04 June 2018
From
Science Speaks
South Africa: Birth defects fears prompt warnings about new ARV

Despite the public concern globally, very little has been said about the impact of the safety warning about dolutegravir on South Africa, the country with the largest HIV treatment programme in the world. The National Department of Health had already planned to introduce a dolutegravir-based first line regimen to replace the existing regimen, hoping to switch the majority of patients starting from last month.

Published
29 May 2018
From
Health-e
Phase 3 registrational data is not sufficient for roll-out of new ARVs in low- and middle-income countries

Phase 3 randomised trials for drug approval in high-income countries do not provide sufficient evidence to support the widespread use of new antiretrovirals in low- and middle-income countries (LMICs), where the majority of people with HIV live. Key missing evidence is typically for pregnant women, people with HIV/TB coinfection and people who have not had resistance testing before starting ART.

Published
15 May 2018
From
HIV i-Base
State-of-the-art HIV drug could curb HIV transmission, improve survival in India

An HIV treatment regimen already widely used in North America and Europe would likely increase the life expectancy of people living with HIV in India by nearly three years and reduce the number of new HIV infections by 23 percent with minimal impact on the country's HIV/AIDS budget.

Published
01 May 2018
From
Science Daily
Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices — But Really 2 Are Best

With the important caveat that what follows represents my opinion and not that of these or any other guidelines, one could easily argue that there are really two primary choices here, not five.

Published
23 April 2018
From
NEJM Journal Watch
Improving Access to Patient Care & Time to Viral Suppression Using HIV Rapid Entry Programs

The CDC has reported that 44% of individuals who are living with HIV are residing in the southern region of the United States; HIV diagnosis rates are higher in the South than they are for Americans overall.

Published
22 March 2018
From
Contagion Live
Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy

A subset of people on ART experience limited or no recovery of CD4+ T cell counts despite achieving and maintaining undetectable HIV viral loads, and these individuals have an elevated risk of illness and death compared with counterparts who obtain greater CD4+ T cell gains.

Published
06 March 2018
From
TAG
An Exciting Act II for the Study That Proved Treating HIV Early Is Best

With a grant to follow their large study population through 2021, researchers hope to gain vital new insights about HIV infection.

Published
25 February 2018
From
Poz
Study finds more than half of patients worldwide don’t access HIV treatment until immune systems are severely compromised

Data from nearly a million patients starting treatment for HIV across the world over the last decade shows 55 percent of them accessed antiretroviral treatment only after their immune cell — or CD4 — counts had dropped below 200, leaving them extremely vulnerable to illnesses and infections.

Published
02 February 2018
From
Science Speaks
GlaxoSmithKline Projects Tough Environment for Triumeq and Tivicay

GlaxoSmithKline is witnessing increased demand for Tivicay as compared to Triumeq. Approximately 40% to 45% of the prescribed Tivicay is used by physicians with Gilead Sciences’ Tenofovir alafenamide (or TAF) therapy, Descovy. The company expects increased competition for its dolutegravir franchise after the launch of Gilead Sciences’ (GILD) integrase inhibitor, bictegravir.

Published
01 February 2018
From
Market Realist
← First12345...18Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.